Sponsors / EWTX
EWTX

Edgewise Therapeutics, Inc.

Company identity checked against sources

Browse linked trials and recorded changes, or follow this company for updates.

Follow company
5Trials in this database
14Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)NCT05291091EWTXPhase 2Completed2026-09-07Actual
A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)NCT05540860EWTXPhase 2Active not recruiting2027-01Estimated
Open-Label Extension of EDG-5506 in Participants With Becker Muscular DystrophyNCT06066580EWTXPhase 2Enrolling by invitation2031-02Estimated
Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene TherapyNCT06100887EWTXPhase 2Active not recruiting2027-03Estimated
A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)NCT06347159EWTXPhase 2Active not recruiting2027-12Estimated

Latest recorded trial changes

Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

NCT05291091 · Edgewise Therapeutics, Inc.

· 4 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Number of adverse events in those treated with sevasemten or placebo Measure: Severity of adverse events in those treated with sevasemten or placebo Measure: Change from Baseline in serum Creatine Kinase Measure: Change from Baseline in the North Star Ambulatory Assessment scale

+ After

Measure: Number of treatment emergent adverse events in those treated with sevasemten or placebo Measure: Severity of treatment emergent adverse events in those treated with sevasemten or placebo Measure: Change from Baseline in serum Creatine Kinase Measure: Change from Baseline in total North Star Ambulatory Assessment score

Completion date type changed

− Before

Estimated

+ After

Actual

Primary completion date changed

− Before

Sep 2026

+ After

7 Sep 2026

Recruitment status changed

− Before

Active not recruiting

+ After

Completed

Check registry source